US Market News
2月前
Bruker Reports First Quarter 2026 Financial ResultsMay 6, 2026 6:30 AM
Business Wire Q1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically Q1-26 GAAP diluted earnings per share (EPS) $0.02; non-GAAP diluted EPS $0.31 Q1-26 Bruker Scientific Instruments (BSI) bookings up high-single digits % organically yoy; BSI book-to-bill ratio above 1.0x for 3rd consecutive quarter Reconfirming previous FY2026 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker’s President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bill ratio was again greater than 1.0x. Healthy bookings trends included solid academic orders for our post-genomic research solutions from outside the US, strong AI-driven demand in semiconductor metrology and in SciY laboratory software, bookings strength in industrial research tools and security detection systems.” He continued: “Importantly, we have introduced impactful new products and solutions at recent scientific and medical conferences, further strengthening our leadership position in NMR, leading the way in spatial biology, and innovating in microbiology and molecular diagnostics. With increased visibility, we reconfirm our FY26 guidance, and we expect a return to organic revenue growth in Q2. All in, Bruker remains poised to deliver significant operating margin expansion and double-digit EPS growth in FY2026.” First Quarter 2026 (Q1-26) Financial Results Bruker’s revenues for the first quarter of 2026 were $823.4 million, an increase of 2.7% compared to $801.4 million in the first quarter of 2025. In Q1-26, revenues decreased organically by 4.4% yoy, while growth from acquisitions was 2.6%, and foreign currency translation had a favorable impact of 4.5% yoy. Q1-26 Bruker Scientific Instruments (BSI) revenues of $759.8 million increased 2.1% yoy, with organic revenue decreasing by 5.0%. Q1-26 Bruker Energy & Supercon Technologies (BEST) revenues of $66.9 million increased 12.8% yoy, with an organic revenue increase of 3.0%, net of intercompany eliminations. Q1-26 GAAP operating income was $10.2 million, compared to GAAP operating income of $31.8 million in the first quarter of 2025. Bruker's Q1-26 non-GAAP operating income was $84.2 million, compared to $101.7 million in the first quarter of 2025, and Q1-26 non-GAAP operating margin was 10.2%, compared to 12.7% in the first quarter of 2025. Q1-26 GAAP diluted earnings per share was $0.02, compared to diluted earnings per share of $0.11 in the first quarter of 2025. Q1-26 non-GAAP diluted EPS was $0.31, compared to $0.47 in the first quarter of 2025. Reconfirming Previous Fiscal Year 2026 (FY26) Financial Outlook Bruker continues to expect FY26 revenues of $3.57 to $3.60 billion, compared to FY25 revenues of $3.44 billion, with 4% to 5% year-over-year reported revenue growth, including: Organic revenue growth of 1% to 2%, M&A revenue growth contribution of approximately 1.5%, and Foreign currency translation revenue tailwind of approximately 1.5% Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. This includes a currency headwind of approximately $0.15, or 8%, implying constant exchange rate (CER) non-GAAP EPS growth of 23% to 25% yoy. Our FY26 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates as of March 31, 2026. For the Company’s outlook for 2026 organic revenue growth, M&A revenue growth, constant exchange rate revenue growth, and constant exchange rate non-GAAP EPS growth, and non-GAAP EPS, each of which are forward-looking non-GAAP measures, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see “Use of Non-GAAP Financial Measures” below for a description of items excluded from our expected non-GAAP EPS. Quarterly Earnings Call Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today, May 6, 2026, at 8:00 am Eastern Daylight Time. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink. A slide presentation will be referenced during the webcast and will be posted to our Investor Relations website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s First Quarter 2026 Earnings Conference Call”. Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10208837/103f221d07a and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call. A telephone replay of the conference call will be available by dialing 1-855-669-9658 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 6572958. The replay will be available beginning one hour after the end of the conference call through June 6, 2026. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com. Use of Non-GAAP Financial Measures To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures: non-GAAP gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating income margin; non-GAAP SG&A expense; non-GAAP interest and other income (expense), net; non-GAAP profit before income taxes; non-GAAP income tax rate; non-GAAP net income and non-GAAP diluted earnings per share. These non-GAAP measures exclude costs related to restructuring actions, impairments, acquisition and related integration expenses, amortization of acquired intangible assets, and other non-operational costs. We also may refer to CER currency revenue growth, CER non-GAAP EPS growth, and free cash flow which are also non-GAAP financial measures. We define the term CER currency revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates. We define the term CER EPS as non-GAAP EPS excluding the effect of changes in foreign currency translation rates. We define free cash flow as net cash provided by operating activities, less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders. The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance. However, we urge investors to review the reconciliation of these financial measures to the comparable GAAP financial measures included in the accompanying tables, and not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance. We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on certain non-GAAP measures and use this information for our planning and forecasting activities. Additional information relating to the non-GAAP financial measures used in this press release and reconciliations to the most directly comparable GAAP financial measures are provided in the tables accompanying this press release following our GAAP financial statements. With respect to our outlook for 2026 non-GAAP organic revenue, non-GAAP M&A revenue, and non-GAAP EPS, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP organic revenue and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future revenues and EPS presented in accordance with GAAP. Forward-Looking Statements Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2026 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER Non-GAAP EPS growth; effects of academic market and tariff dynamics on our future financial results and our ability to mitigate such effects in the future; management’s expectations for the impact of foreign currency and acquisitions; the effects of our expanded cost savings initiatives; and for future financial and operational performance and business outlook; future economic conditions; and statements found under the “Use of Non-GAAP Financial Measures” section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, (1) the length and severity of any recession and the impact on global economic conditions, (2) the impact of supply chain challenges, including inflationary pressures, (3) the impact of geopolitical instability and tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from the ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, (4) the conflict in Israel, Palestine and surrounding areas and hostilities in the Middle East, including heightened tensions in Iran, and the possible expansion of such conflicts and potential geopolitical consequences and global instability, (5) the ongoing tensions between the United States and China, tariff increases or uncertainties and trade policy changes and restrictions, and the increasing potential of conflict involving countries in Asia that are critical to our supply chain operations, such as Taiwan and China, (6) continued volatility in the capital markets, (7) the impact of increased interest rates, (8) the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, (9) our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, (10) the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, (11) changes in governmental regulations, intellectual property rights, and litigation, (12) exposure to foreign currency fluctuations, (13) the impact of foreign currency exchange rates, (14) our ability to service our debt obligations and fund our anticipated cash needs, (15) the effect of a concentrated ownership of our common stock, (16) the loss of key personnel, (17) payment of future dividends, (18) the impact (if any) of macroeconomic issues, including uncertainties related to trade policies or tariff regulations, and (19) other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by applicable law. Bruker Corporation PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in millions, except per share data) Three Months Ended
March 31, 2026 2025 Revenue $ 823.4 $ 801.4 Cost of revenue 443.6 410.2 Gross profit 379.8 391.2 Operating expenses: Selling, general and administrative 242.1 225.4 Research and development 101.3 97.1 Other charges, net 26.2 36.9 Total operating expenses 369.6 359.4 Operating income 10.2 31.8 Interest and other income (expense), net 11.7 (6.7 ) Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries (a) 21.9 25.1 Income tax provision 2.5 8.7 Equity in (losses) income of unconsolidated investees, net of tax (3.7 ) 0.4 Consolidated net income 15.7 16.8 Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries 1.3 (0.6 ) Net income attributable to Bruker Corporation $ 14.4 $ 17.4 Dividends on Series A Mandatory Convertible Preferred Stock 10.9 — Net income attributable to Bruker Corporation common shareholders $ 3.5 $ 17.4 Net income per common share attributable to Bruker Corporation common shareholders: Basic $ 0.02 $ 0.11 Diluted $ 0.02 $ 0.11 Weighted average common shares outstanding: Basic 152.2 151.6 Diluted 152.7 151.9 a) On subsequent pages this is referred to as “Profit before income tax”. Bruker Corporation REVENUE (unaudited and in millions) Three Months Ended
March 31, 2026 2025 Revenue by Segment: Bruker BioSpin $ 197.5 $ 207.8 Bruker CALID 316.3 280.1 Bruker Nano 246.0 256.6 BSI Revenue Total 759.8 744.5 BEST 66.9 59.3 Eliminations (3.3 ) (2.4 ) Total revenue $ 823.4 $ 801.4 Revenue by End Customer Geography: United States $ 221.9 $ 217.4 Europe 321.6 285.2 Asia Pacific 208.7 232.6 Other 71.2 66.2 Total revenue $ 823.4 $ 801.4 Bruker Corporation
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES
(unaudited and in millions, except per share data) The tables below present the GAAP to Non-GAAP reconciliation for the three months ended March 31, 2026, and March 31, 2025, respectively, for the following measures: Gross Profit and Gross Profit Margin; Selling, General and Administrative (“SG&A”) Expenses; Operating Income and Operating Income Margin; Interest and Other Income (Expense), net; Profit before Income Taxes; Net Income Attributable to Bruker Corporation Common Shareholders; Diluted net income per common share; and Income Tax rate. Gross Profit Gross Profit Margin SG&A Expenses Operating Income Operating Income Margin Interest and other income (expense), net Profit before income tax (a) Net Income attributable to Bruker Corporation Common Shareholders Diluted net income per common share Income Tax Rate Three Months Ended March 31, 2026: GAAP $ 379.8 46.1 % $ 242.1 $ 10.2 1.2 % $ 11.7 $ 21.9 $ 3.5 $ 0.02 11.4 % Non-GAAP adjustments: Restructuring costs 9.5 1.2 % — 17.8 2.2 % — 17.8 17.8 0.12 — Acquisition-related costs 3.4 0.4 % — 7.5 0.9 % — 7.5 7.5 0.05 — Purchased intangibles amortization 16.7 2.0 % (15.7 ) 32.5 3.9 % — 32.5 32.5 0.21 — Intangible assets impairment charges 0.7 0.1 % — 2.7 0.3 % — 2.7 2.7 0.02 — Gain on remeasurement of previously held equity interest — — — — — (12.2 ) (12.2 ) (12.2 ) (0.08 ) Investments related adjustments — — — — — (1.2 ) (1.2 ) (1.2 ) (0.01 ) — Lease and fixed asset impairment charges 1.8 0.2 % — 12.7 1.5 % — 12.7 12.7 0.08 — Other costs (0.1 ) — — 0.8 0.2 % — 0.8 0.8 0.01 — Tax effect of above Non-GAAP adjustments — — — — — — — (20.3 ) (0.13 ) 16.2 % Equity in income (losses) of unconsolidated investees, net of tax — — — — — — — 3.7 0.02 — Noncontrolling interests related to non-GAAP adjustments — — — — — — — (0.5 ) — — Total Non-GAAP adjustments 32.0 3.9 % (15.7 ) 74.0 9.0 % (13.4 ) 60.6 43.5 0.29 16.2 % Non-GAAP $ 411.8 50.0 % $ 226.4 $ 84.2 10.2 % $ (1.7 ) $ 82.5 $ 47.0 $ 0.31 27.6 % Three Months Ended March 31, 2025: GAAP $ 391.2 48.8 % $ 225.4 $ 31.8 4.0 % $ (6.7 ) $ 25.1 $ 17.4 $ 0.11 34.7 % Non-GAAP adjustments: Restructuring costs 2.6 0.3 % — 10.2 1.3 % — 10.2 10.2 0.07 — Acquisition-related costs 2.3 0.3 % — 8.6 1.1 % — 8.6 8.6 0.06 — Purchased intangibles amortization 14.0 1.7 % (13.1 ) 27.3 3.4 % — 27.3 27.3 0.18 — Acquisition-related litigation charges — — — 18.6 2.3 % — 18.6 18.6 0.12 — Investments related adjustments — — — — — 2.0 2.0 2.0 0.01 — Other costs 0.8 0.2 % — 5.2 0.6 % — 5.2 5.2 0.03 — Tax effect of above Non-GAAP adjustments — — — — — — — (18.2 ) (0.11 ) (0.6 )% Other Discrete Items — — — — — — — — — (6.4 )% Equity in income (losses) of unconsolidated investees, net of tax — — — — — — — (0.4 ) — — Total Non-GAAP adjustments 19.7 2.5 % (13.1 ) 69.9 8.7 % 2.0 71.9 53.3 0.36 (7.0 )% Non-GAAP $ 410.9 51.3 % $ 212.3 $ 101.7 12.7 % $ (4.7 ) $ 97.0 $ 70.7 $ 0.47 27.7 % (a) Referred to as “Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries” in the GAAP condensed consolidated statements of operations. Bruker Corporation
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES - Continued
(unaudited and in millions, except per share data) The tables below present the GAAP to Non-GAAP reconciliation for weighted average common shares outstanding (Diluted), CER currency revenue, organic revenue, and free cash flow: Three Months Ended
March 31, 2026 2025 GAAP Weighted Average Common Shares Outstanding (Diluted) 152.7 151.9 Stock options, restricted stock units, and employee stock purchase plan — — Series A Mandatory Convertible Preferred Stock (a) — — Non-GAAP Weighted Average Common Shares Outstanding (Diluted) 152.7 151.9 (a) The impact of the Series A Mandatory Convertible Preferred Stock (MCP) calculated under the if-converted method was anti-dilutive for both GAAP and Non-GAAP EPS for the three months ended March 31, 2026. There was no MCP outstanding for the comparative period in 2025. Total Bruker Bruker Scientific Instruments (a) BEST Three Months Ended March 31, 2026 yoy growth (c) 2025 2026 yoy growth (c) 2025 2026 yoy growth (c) 2025 GAAP revenue $ 823.4 2.7% $ 801.4 $ 759.8 2.1% $ 744.5 $ 63.6 11.8% $ 56.9 Effect of changes in foreign currency translation rates 36.6 (10.4 ) 31.6 (9.2 ) 5.0 (1.2 ) Non-GAAP CER currency revenue 786.8 (1.8)% 811.8 728.2 (2.2)% 753.7 58.6 3.0% 58.1 Acquisitions (b) 20.8 69.2 20.8 69.2 - - Non-GAAP Organic revenue $ 766.0 (4.4)% $ 742.6 $ 707.4 (5.0)% $ 684.5 $ 58.6 3.0% $ 58.1 (a) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID, and NANO Segments as presented in our Annual Report on Form 10-K for the year ended December 31, 2025. (b) We define the term acquisitions revenue as GAAP revenue from M&A activities excluding the effect of changes in foreign currency translation rates. (c) Yoy growth rates are calculated as the percentage increase (or decrease) in respective line items relative to GAAP revenue in the comparable prior year. Three Months Ended
March 31, 2026 2025 Net cash provided by operating activities $ 71.2 $ 65.0 Non-GAAP adjustments: Purchases of property, plant and equipment (24.2 ) (26.0 ) Non-GAAP free cash flow $ 47.0 $ 39.0 Bruker Corporation PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions) March 31,
2026 December 31,
2025 ASSETS Current assets: Cash and cash equivalents $ 133.4 $ 298.8 Accounts receivable, net 542.7 544.9 Inventories 1,121.5 1,094.6 Other current assets 306.0 274.2 Total current assets 2,103.6 2,212.5 Property, plant and equipment, net 719.6 744.8 Goodwill, intangibles, net and other long-term assets 3,307.5 3,284.1 Total assets $ 6,130.7 $ 6,241.4 LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS’ EQUITY Current liabilities: Current portion of long-term debt and finance lease obligations $ 8.4 $ 16.6 Accounts payable 269.1 215.9 Deferred revenue and customer advances 479.7 441.3 Other current liabilities 597.9 605.4 Total current liabilities 1,355.1 1,279.2 Long-term debt 1,662.9 1,852.5 Other long-term liabilities 609.9 599.4 Redeemable noncontrolling interests 35.8 36.8 Total shareholders' equity 2,467.0 2,473.5 Total liabilities, redeemable noncontrolling interests and shareholders' equity $ 6,130.7 $ 6,241.4 Bruker Corporation PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (in millions) Three Months Ended
March 31, 2026 2025 Cash flows from operating activities: Consolidated net income $ 15.7 $ 16.8 Adjustments to reconcile consolidated net income to cash flows from operating activities: Depreciation and amortization 58.3 50.4 Other non-cash expenses, net 21.4 (11.5 ) Changes in operating assets and liabilities, net of acquisitions and divestitures: Accounts payable and accrued expenses 11.2 26.4 Inventories (47.2 ) (28.4 ) Other changes in operating assets and liabilities, net 11.8 11.3 Net cash provided by operating activities 71.2 65.0 Cash flows from investing activities: Purchases of property, plant and equipment (24.2 ) (26.0 ) Cash paid for acquisitions, net of cash acquired (16.0 ) (1.1 ) Other investing activities, net 0.5 1.0 Net cash used in investing activities (39.7 ) (26.1 ) Cash flows from financing activities: Repayments of revolving lines of credit — (167.9 ) Proceeds from revolving lines of credit — 139.9 Repayment of long-term debt (181.3 ) (7.7 ) Proceeds from long-term debt — 2.9 Payment of dividends to Series A Mandatory Convertible Preferred Shareholders (11.0 ) — Payment of dividends to common shareholders (7.6 ) (7.7 ) Repurchase of common stock — (10.0 ) Other financing activities, net (5.0 ) (0.7 ) Net cash used in financing activities (204.9 ) (51.2 ) Effect of exchange rate changes on cash, cash equivalents and restricted cash 7.9 13.3 Net increase (decrease) in cash, cash equivalents and restricted cash (165.5 ) 1.0 Cash, cash equivalents and restricted cash at beginning of period 303.1 186.7 Cash, cash equivalents and restricted cash at end of period $ 137.6 $ 187.7 View source version on businesswire.com: https://www.businesswire.com/news/home/20260506313470/en/ Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com Original: Bruker Reports First Quarter 2026 Financial Results
US Market News
3月前
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak ManagementApril 17, 2026 6:00 AM
Business Wire
MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target plates
MALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria
MALDI Biotyper®: Early KOL access to a novel cloud-based identification solution, enabling identification against several specialist, expert-curated libraries
MALDI Biotyper®: Ongoing broad, multi-year clinical and translational study programs advancing automation, potential future claims, and next-generation analytics, including:
IVDR-compliant clinical validation studies evaluating automated sample preparation workflows, covering both colony-based cultures (MBT PrepMatic™) and positive blood cultures (MBT SepsiMatic®)
U.S. clinical studies intended to support upcoming identification claims for mycobacteria and filamentous fungi, with FDA submission targeted for 2026
Ongoing clinical evaluation of MBT FAST, a rapid phenotypic antimicrobial susceptibility testing approach, aiming to enable IVDR-compliant same-day results from positive blood cultures and agar colonies for Enterobacteriaceae
Exploratory, data-driven research studies presented at ESCMID, including AI-based antibiotic resistance prediction for Staphylococcus aureus, derived from large MALDI Biotyper spectral datasets
IR Biotyper®: Enhanced outbreak detection with IR Tracker for surveillance of hospital-acquired infections (HAIs) and new classifiers for Salmonella Typhi, STEC, and Shigella sp. detection
MBioSEQ™ Ridom Typer: New software version, including TB-Profiler antimicrobial resistance (AMR) determination, and GAMBIT bacterial species identification supporting MALDI / IR Biotyper®-triggered WGS reflex testing workflows, with result application performed under laboratory responsibility
Introduction of Molzym as a part of Bruker Microbiology and Infection Diagnostics
At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next-generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high-performance solutions that support laboratories in addressing evolving infectious disease challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417265432/en/MBT Easy T® Kit – Bruker’s consumables kit providing ready-to-use solvents and sample applicators for streamlined sample preparation in MALDI Biotyper®-based microbial identification
MALDI Biotyper® Workflow and Identification Enhancements
To further streamline routine MALDI-TOF workflows, Bruker introduces the proprietary MBT Easy T® Kit (RUO and IVDR), a consumables kit designed to simplify and standardize sample transfer steps to MALDI target plates. The kit includes ready-to-use reagents and applicators, supporting up to 2,000 samples, while enabling room temperature storage and reducing chemical waste.
In parallel, Bruker expands its MALDI Biotyper® reference libraries to more than 5,300 species, including bacteria, yeasts, filamentous fungi, and mycobacteria (RUO). The latest library updates add more than 600 new species and significantly strengthen species coverage, particularly for the dedicated filamentous fungi MyT workflow which benefits from ~30% stronger species coverage. Corresponding IVDR-registered library expansions are currently in progress.
To extend access to specialized identification content beyond local installations, Bruker is offering early access to a cloud-based MALDI identification solution (RUO) for selected key opinion leaders and expert laboratories. This approach enables research use identification using specialist libraries curated by domain experts, within the MBT Compass HT environment. Initial expert libraries include yeast collections, anaerobic bacteria libraries developed by academic partners, and mosquito libraries supporting malaria vector monitoring and research. The cloud infrastructure allows visibility of library provenance and provides a foundation for future capabilities such as exclusive libraries, online system monitoring, and software updates.
Bruker continues to advance automation across sample preparation workflows with MBT PrepMatic™ and MBT SepsiMatic® systems, both currently under evaluation in IVDR-compliant clinical validation studies. MBT PrepMatic™ is designed to enable semi- to fully automated colony picking from Petri dish cultures and preparation of MALDI target plates. MBT SepsiMatic® is designed to support a fully automated workflow from positive blood culture bottles to prepared MALDI target plates, with the potential to produce purified samples containing viable cells for downstream analysis.
Advanced Clinical and Research Applications
Bruker is progressing multiple advanced applications for MALDI-based microbiology. In the United States, clinical studies are underway to support upcoming claims for mycobacteria and filamentous fungi identification, with FDA submissions planned for 2026.
Clinical validation studies are underway on rapid phenotypic antimicrobial susceptibility testing (AST) using MALDI-TOF MS, aimed at enabling same-day results from positive blood cultures and agar colonies for Enterobacteriaceae. This approach explores the use of machine-learning-based growth assessment and aligns conceptually with CLSI- and EUCAST-guided broth microdilution principles.
At ESCMID Global 2026, Bruker is also presenting poster data from exploratory research on AI-driven antibiotic resistance prediction for Staphylococcus aureus, with AUROC >0.8, based on more than 2,600 MALDI Biotyper® spectra (RUO). Further studies with expanded scope are ongoing.
Hospital Hygiene and Outbreak Management
In the area of hospital hygiene and epidemiology, Bruker expands IR Biotyper® applications (GP) with IR Tracker for surveillance of hospital-acquired infections (HAIs) and new classifiers for clinically and epidemiologically significant organisms. Newly supported targets include Salmonella Typhi, Shiga toxin-producing E. coli (STEC), and Shigella species - pathogens associated with specific treatment requirements, high infectivity, and public health reporting obligations. These enhancements support rapid differentiation and classification to aid outbreak detection and infection control efforts.
Reflex NGS and Culture-Independent Diagnostics
Bruker introduces a new software version of its MBioSEQ™ Ridom Typer (RUO), featuring short and long read whole genome sequencing (WGS) data analysis for research and expert laboratory applications. The software now includes TB-Profiler-based antimicrobial resistance (AMR) determination and GAMBIT bacterial species identification, supporting MALDI / IR Biotyper®-triggered WGS reflex workflows as part of laboratory-defined analysis processes.
In addition, Bruker announces the integration of Molzym following its acquisition in late 2025, further strengthening the company’s Microbiology & Infection Diagnostics portfolio. Molzym brings expertise in culture-independent pathogen diagnostics, including its unique and patented MolYsis™ host-DNA depletion technology, which selectively removes host DNA to enable highly sensitive detection of microbial DNA in low-biomass and blood samples for subsequent sequencing analysis.
“In routine MALDI-TOF identification, having critical reagents readily available in a standardized format is essential,” said Kirsten Schönfeld, Diplom-Biologin, Institut Dr. Nowak GmbH, Germany. “The MBT Easy T® Kit provides pre-filled, ready-to-use solvent ampoules, including formic acid, which will simplify logistics and daily laboratory operations. This helps maintain a robust and streamlined MALDI Biotyper workflow in a clinical setting.”
Dr. Wolfgang Pusch, President of Bruker’s Microbiology & Infection Diagnostics Division, added: “Feedback like this underscores why we continue to invest in practical innovations that strengthen everyday laboratory workflows. Across microbial identification and outbreak analysis, Bruker is pursuing a broad and sustained innovation initiative - significantly expanding our reference libraries, introducing new sample preparation options to enable the highest level of standardization, and advancing exploratory artificial-intelligence-based approaches for antibiotic resistance prediction from MALDI spectra. In parallel, we are driving the development of automation for sample preparation from both colonies and positive blood cultures, initiating clinical studies for MALDI Biotyper®-based rapid antimicrobial susceptibility testing, and further expanding the analytical capabilities of the IR Biotyper®. At the same time, we continue to refine our NGS-based MBioSEQ™ Ridom Typer , including ongoing, research-use-focused enhancements for tuberculosis antimicrobial resistance profiling.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260417265432/en/
Trade Press & Customer Contact:
Alessandro Abramo
Director Marketing & Product Management
Bruker Microbiology & Infection Diagnostics Division
T: +39-348-360-9058
E: alessandro.abramo@bruker.com
Investor Contact:
Joe Kostka
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Original: Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
US Market News
3月前
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026April 17, 2026 6:00 AM
Business Wire
At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius® system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO® automates the entire workflow - from patient sample to diagnostic result - enhancing laboratory efficiency and supporting higher-throughput volume testing needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417698008/en/MyGenius PRO® installed at a leading European transplant center supporting routine infectious disease testing
At launch, the MyGenius PRO® IVDR menu will include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, are planned throughout 2026.
The MyGenius PRO® platform was developed in a collaboration between ELITechGroup, a Bruker company, and Hitachi High Tech-Corporation (Hitachi High-Tech), combining complementary expertise in molecular assays, automation and engineering. Hitachi High-Tech will introduce the platform under the tradename LABOSPECT GA-5 in Japan. This system comes with Bruker molecular diagnostic assays for infectious disease testing in accordance with Japanese diagnostic regulations.
During a recent interview, Dr. Pierangelo Clerici, President of AMCLI (Italian Association of Clinical Microbiologists), emphasized the importance of high throughput in microbiology laboratories: “Timely diagnosis is critical in microbiology and virology. Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring, while enabling laboratories to streamline workflows and ensure compliance with IVDR regulations.”
The launch of MyGenius PRO® marks a new chapter in Bruker’s Microbiology & Infection Diagnostics molecular diagnostics strategy, further expanding a portfolio that includes InGenius®, BeGenius®, a rapidly growing CE-IVD assay menu, and novel LiquidArray® assays for advanced multiplexing and more affordable syndromic panel testing.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
About Hitachi High-Tech
Hitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Hitachi High-Tech also provide high value-added solutions in industrial fields such as mobility, environment and energy, etc.
For further information, visit https://www.hitachi-hightech.com/global/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260417698008/en/
Trade Press & Customer Contact:
Alessandro Abramo
Director Marketing & Product Management
Bruker Microbiology & Infection Diagnostics Division
T: +39-348-360-9058
E: alessandro.abramo@bruker.com
Investor Contact:
Joe Kostka
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Original: Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
wEaReLeGiOn
17年前
Bruker Corporation (NASDAQ: BRKR) today reported financial
results for the third quarter ended September 30, 2009.
Lookin' good :)
Third Quarter 2009 Highlights
* Revenue $265.1 million
* GAAP Net Income $16.4 million
* GAAP EPS $0.10 per diluted share
* Free cash flow $14.2 million
Financial Results
In the third quarter of 2009, revenue was $265.1 million, an increase of 9.5% compared to revenue of $242.1 million in the third quarter of 2008. Excluding the effect of foreign currency translation, third quarter 2009 revenue increased 11.4% year-over-year. GAAP net income for the third quarter of 2009 was $16.4 million, or $0.10 per diluted share, compared to GAAP net income of $17.8 million, or $0.11 per diluted share, in the third quarter of 2008. Included in GAAP EPS in the third quarter of 2008 were (i) one-time tax benefits of $0.07 per diluted share and (ii) non-cash stock-based compensation expense of ($0.01) per diluted share. Included in GAAP EPS in the third quarter of 2009 was non-cash stock-based compensation expense of ($0.01) per diluted share.
For the nine months ended September 30, 2009, revenue was $748.1 million, a decrease of 5.5% compared to revenue of $791.9 million in the first three quarters of 2008. Excluding the effect of foreign currency translation, revenue for the nine months ended September 30, 2009 increased by 0.5% year-over-year. GAAP net income for the nine months ended September 30, 2009 was $37.7 million, or $0.23 per diluted share, compared to GAAP net income of $38.7 million, or $0.23 per diluted share, for the nine months ended September 30, 2008. Included in GAAP EPS for the nine months ended September 30, 2008 were (i) one-time tax benefits of $0.07 per diluted share, (ii) Bruker BioSpin acquisition related expenses of ($0.04) per diluted share, and (iii) non-cash stock-based compensation expense of ($0.02) per diluted share. Included in GAAP EPS for the nine months ended September 30, 2009 was non-cash stock-based compensation expense of ($0.02) per diluted share.
Free cash flow was $14.2 million in the third quarter of 2009, and $58.4 million for the nine months ended September 30, 2009, compared to a use of cash of ($11.9) million for the third quarter of 2008, and a use of cash of ($20.9) million for the nine months ended September 30, 2008. During the third quarter of 2009, Bruker repaid $19.3 million of debt, ending the quarter with cash and cash equivalents of $150.5 million, and net debt of $0.8 million, compared to net debt of $127.6 million at the end of the third quarter of 2008.
Comment and Outlook
Frank Laukien, Bruker’s President and CEO, commented: “We are pleased with our double-digit currency-adjusted third quarter 2009 year-over-year revenue growth, with our solid sequential improvements in revenue, operating margins and net income during the first three quarters of 2009, and with our strong free cash flow year-to-date. Our third quarter 2009 operating income increased more than 70% year-over-year, and our operating margin improved sequentially by 180 basis points, when compared to the second quarter 2009.”
Dr. Laukien continued: “During the third quarter we have seen positive sequential trends in bookings throughout the company, even in the divisions with a greater industrial markets exposure. We have also begun to see robust bookings from our academic and government customers who are benefiting from various global government stimulus programs. While we expect a strong fourth quarter of 2009, we believe that most of the anticipated positive revenue and margin effects from global stimulus orders will be reflected in Bruker’s financial results in 2010 and 2011.”
Segment Information
After Bruker’s acquisition of the ACCEL Research Instruments business on April 1, 2009, starting with the second quarter of 2009, Bruker has established two new reportable segments:
1) The Bruker Scientific Instruments (BSI) segment which consists of the four divisions Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics.
2) The Bruker Energy & Supercon Technologies (BEST) segment which combines the acquired ACCEL RI business, and the superconductor and supercon devices business, which was previously called Bruker Advanced Supercon, Inc.
Revenue in the BSI segment for the nine months ended September 30, 2009 was $716.5 million, compared to BSI revenue of $767.3 million for the nine months ended September 30, 2008. Excluding the effects of foreign currency translation, for the first nine months of 2009, BSI revenue decreased by 1.0% year-over-year. BSI net income for the nine months ended September 30, 2009 was $41.7 million, compared to $45.3 million for the nine months ended September 30, 2008. BSI earnings per diluted share for the nine months ended September 30, 2009 were $0.25, compared to $0.27 for the nine months ended September 30, 2008.
Revenue in the BEST segment for the nine months ended September 30, 2009 was $36.0 million, compared to BEST revenue of $32.5 million for the nine months ended September 30, 2008. Excluding the effects of foreign currency translation, for the first nine months of 2009, BEST revenue increased by 23.4% year-over-year. BEST net loss for the nine months ended September 30, 2009 was ($5.0) million, compared to a net loss of ($6.8) million for the nine months ended September 30, 2008. BEST loss per diluted share for the nine months ended September 30, 2009 was ($0.03), compared to ($0.04) for the nine months ended September 30, 2008.
Following at the end of this press release are reconciliations of certain non-GAAP measures presented in this release.
USE OF NON-GAAP FINANCIAL MEASURES
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the measures of non-GAAP revenue, non-GAAP net income, non-GAAP EPS by reportable segment, and non-GAAP free cash flow for Bruker Corporation. We believe that such non-GAAP measures help investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measures included in this press release are not meant to be a better presentation or a substitute for results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying table. Specifically:
* Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the nine months ended September 30, 2009 and 2008
* Reconciliation of Free Cash Flow
EARNINGS CONFERENCE CALL
Bruker Corporation will host an operator-assisted earnings conference call at 9:00 a.m. Eastern Daylight Time on Thursday, October 29, 2009. To listen to the webcast, investors can go to http://ir.bruker.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 800-688-0796, or +1-617-614-4070 outside the US and Canada. Investors should refer to the Bruker Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside the US and Canada, and then entering replay pass code 94562291. For more information, please visit http://ir.bruker.com
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties, that could cause actual future results to differ materially from those projected including, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Bruker Corporation
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in millions, except per share data)
Three Months Ended September 30, Nine Months Ended September 30,
2009 2008 2009 2008
Product revenue $ 230.7 $ 211.8 $ 655.8 $ 700.4
Service revenue 32.4 28.8 87.6 87.7
Other revenue 2.0 1.5 4.7 3.8
Total revenue 265.1 242.1 748.1 791.9
Cost of product revenue 127.9 114.6 364.8 382.3
Cost of service revenue 18.0 16.4 50.2 54.9
Total cost of revenue 145.9 131.0 415.0 437.2
Gross profit 119.2 111.1 333.1 354.7
Operating Expenses:
Sales and marketing 44.1 45.2 130.6 136.7
General and administrative 17.5 17.7 50.8 51.7
Research and development 31.6 33.1 91.8 100.8
Acquisition related, net - - (0.6 ) 6.2
Total operating expenses 93.2 96.0 272.6 295.4
Operating income 26.0 15.1 60.5 59.3
Interest and other income (expense), net (1.8 ) 0.8 (4.6 ) (7.8 )
Income before income tax provision and
noncontrolling interest in consolidated subsidiaries 24.2 15.9 55.9 51.5
Income tax provision 8.1 (2.0 ) 18.5 12.5
Net income 16.1 17.9 37.4 39.0
Net income (loss) attributable to noncontrolling interests (0.3 ) 0.1 (0.3 ) 0.3
Net income attributable to Bruker Corporation $ 16.4 $ 17.8 $ 37.7 $ 38.7
Net income per common share attributable to:
Bruker Corporation shareholders:
Basic $ 0.10 $ 0.11 $ 0.23 $ 0.24
Diluted $ 0.10 $ 0.11 $ 0.23 $ 0.23
Weighted average shares outstanding:
Basic 163.5 162.8 163.4 162.5
Diluted 165.0 165.9 164.7 165.6
Bruker Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in millions)
September 30, December 31,
2009 2008
ASSETS
Current assets:
Cash, short-term investments and restricted cash $ 150.5 $ 167.7
Accounts receivable, net 151.7 171.9
Inventories 443.6 425.1
Other current assets 72.7 56.0
Total current assets 818.5 820.7
Property and equipment, net 226.4 221.3
Intangible and other assets 79.3 74.3
Total assets $ 1,124.2 $ 1,116.3
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings $ 30.9 $ 41.0
Accounts payable 45.5 43.3
Customer deposits 197.1 199.6
Other current liabilities 247.5 235.8
Total current liabilities 521.0 519.7
Long-term debt 120.4 182.8
Other long-term liabilities 109.3 101.1
Total shareholders' equity 373.5 312.7
Total liabilities and shareholders' equity $ 1,124.2 $ 1,116.3
Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the nine months ended September 30, 2009 and 2008 (unaudited)
(in millions, except per share data)
Bruker
Bruker Energy & Corporate,
Scientific Supercon Adjustments GAAP
September 30, 2009: Instruments Technologies & Eliminations Consolidated
Revenue $ 716.5 $ 36.0 $ (4.4 ) $ 748.1
Operating Income (Loss) 63.4 (4.3 ) 1.4 60.5
Net Income (Loss) 41.7 (5.0 ) 1.0 37.7
Net Income (Loss) Per Diluted Share $ 0.25 $ (0.03 ) $ 0.01 $ 0.23
Diluted Shares Outstanding 164.7 163.4 164.7 164.7
September 30, 2008:
Revenue $ 767.3 $ 32.5 $ (7.9 ) $ 791.9
Operating Income (Loss) 65.7 (6.6 ) 0.2 59.3
Net Income (Loss) 45.3 (6.8 ) 0.2 38.7
Net Income (Loss) Per Diluted Share $ 0.27 $ (0.04 ) $ 0.00 $ 0.23
Diluted Shares Outstanding 165.6 162.5 165.6 165.6
Reconciliation of Free Cash Flow of Bruker Corporation (unaudited)
(in millions)
Three Months Ended Nine Months Ended
September 30, September 30,
2009 2008 2009 2008
Cash flow from operations $ 16.0 $ 0.8 $ 67.3 $ 18.9
Capital expenditures (1.8 ) (12.7 ) (8.9 ) (39.8 )
Free cash flow $ 14.2 $ (11.9 ) $ 58.4 $ (20.9 )
MSC290
17年前
Bruker to Present Major Instrument Innovations
Aug. 27, 2009 - By: Business Wire
The 18th International Mass Spectrometry Conference (IMSC) will open on August 30th, in Bremen, Germany, which is also the home of Bruker Daltonics, a leading developer of innovative life science mass spectrometry tools.
In addition to supporting IMSC as a Platinum Sponsor, and presenting more than 50 contributions in the scientific conference program, Bruker Daltonics has organized various workshops, customer days, exhibitions and company tours to present its mass spectrometry innovations to the scientific community:
* Sunday, August 30th: Bruker Daltonics International Users Conference
* Monday, August 31st and Tuesday, September 1st: Workshop Series “Achieving Highest Confidence with Complex Small Molecules Samples”, and “New Tools for Biomarker Discovery”, presented by MS experts including Don Richards (Pfizer Central Research Ltd., UK), Tony Bristow (AstraZeneca, UK), Gary Corthals (TCB, Finland), and Bernhard Kuester,(TU Munich, Germany)
* Monday, August 31st and Tuesday, September 1st: Live instrument demonstrations at our Bremen factory facility
* Wednesday, September 2nd: Bruker Daltonics factory tours running throughout the day;
At IMSC 2009, Bruker presents for the first time in Europe a number of truly innovative, high performance mass spectrometry platforms demonstrating Bruker’s “Continuing Revolution” campaign to enable the life science community for an ever increasing range of scientific investigations, as well as for advanced applied and clinical methods:
* maXis™ enabled with ETD , a technique set to revolutionize the way scientists study protein primary and secondary structures, modifications, folding and function, will be demonstrated live at IMSC 2009 to an audience of international scientists. The maXis™ is a unique high-speed Ultra-High Resolution TOF (UHR-TOF) mass spectrometer for highest performance with no-compromise for small molecule and proteomics applications. Following on from its successful introduction in 2008 and the large number of installations completed worldwide in many leading pharmaceutical and academic laboratories, the next generation maXis including high-performance ETD is now a reality. For further information: www.bdal.com/maXis
* ultrafleXtreme™ is the only fully 1 kHz MS and MS/MS enabled MALDI-TOF/TOF system available and incorporates the new smartbeam™-II laser technology and a 4 GHz digitizer. Its unmatched proteomics performance shows broad-band mass resolving power up to 40,000 and 1 ppm mass accuracy. Its unique flexibility allows LC-MALDI TOF/TOF, label-free quantitation, top-down intact protein analysis, Edmass™ protein sequencing, polymer characterization and oligonucleotide analysis. A rapid self-cleaning ion source, industry-leading imaging software and laser focal diameters down to 10 µm deliver the most powerful and complete MALDI imaging system on the market. In addition, as recently announced, the integration of the Carl Zeiss’ MIRAX Virtual Slide Scanner has enabled revolutionary advances in non-targeted molecular histology with high spatial resolution (research use only). Further information: www.bdal.com/ultrafleXtreme
* amaZon™ is the fastest ion trap available today with a 52,000 u/sec scan rate at 0.58 u mass resolution. The integration of novel, proprietary dual ion funnel technology, has increased sensitivity by an order of magnitude, and the second-generation ETD / PTR module for proteomics offers unmatched ETD sensitivity with high robustness and ease-of-use. A mass resolving power up to 20,000 in full scan mode across m/z 50-3000 makes top-down ETD experiments a reality. The fast MS data acquisition speed of 20 Hz with zero-delay polarity switching also makes amaZon the ideal instrument for all fast screening applications based on spectral libraries, including clinical toxicology and forensics. Further information: www.bdal.com/amaZon
* solariX™ is a next generation hybrid FTMS system, delivering a 10-fold improvement in sensitivity, an 8-fold gain in broadband ultra-high resolution (>1,000,000 at 7 T), and sub-ppm mass accuracy over a wide dynamic range. The complete engineering redesign makes this instrument extremely robust, uniquely powerful whilst also easy to use. SolariX is ideal for the analysis of very complex mixtures in top-down proteomics, with both ETD and ECD now as standard proteomics tools. Additional applications include petroleomics, metabolomics, and small-molecule drug and metabolite MALDI imaging on the dual ESI/MALDI source system. At the IMSC 2009, Bruker Daltonics announces the availability of the world’s first 18 tesla (T) magnet designed for FTMS applications. This unique magnet system represents the world’s highest field FTMS magnet, providing record-breaking scientific capabilities that can be applied to some of today’s most important, complex and challenging protein, polymer and small molecule analyses. For further information: www.bdal.com/solariX
Bruker Daltonics staff will be available for in-depth meetings during exhibit hours at Bruker's IMSC booth D in Hall 4.0, Monday through Friday. On Monday evening, the Hospitality Suite at the Lloyd room, CCB, is open 6 – 9 pm. A special evening event is organized for Tuesday in the famous “Bremer Ratskeller” located in the 16th century Bremen town hall. An evening reception will take place on Wednesday 5 – 7 pm at the Bruker booth in Hall 4.0. For more information on Bruker’s IMSC events, please visit www.bdal.com/imsc
http://ca.sys-con.com/node/1084798
wEaReLeGiOn
17年前
Bruker Corporation Reports Second Quarter
2009 Financial Results
http://ih.advfn.com/p.php?pid=nmona&cb=1248880657&
article=38816580&symbol=N^BRKR
8K http://ih.advfn.com/p.php?pid=nmona&cb=1248880684&article=38816797&symbol=N^BRKR
Bruker Corporation (NASDAQ: BRKR) today reported financial results for the second quarter ended June 30, 2009.
Second Quarter 2009 Highlights
* Revenue $252.5 million
* GAAP Net Income $12.9 million
* GAAP EPS $0.08 per diluted share
* Free cash flow $32.8 million
* After acquisition of ACCEL RI business on April 1, 2009, Bruker established new Energy & Supercon Technologies segment
* Bruker’s Scientific Instruments segment launched numerous innovative products with compelling performance and capabilities: Avance III 1,000 MHz NMR, ultrafleXtreme TOF/TOF, amaZon ion trap, solariX FTMS and 263 GHz EPR
Financial Results
In the second quarter of 2009, revenue was $252.5 million, a decrease of 18.9% compared to revenue of $311.5 million in the second quarter of 2008. Excluding the effect of foreign currency translation, second quarter 2009 revenue decreased 11.1% year-over-year. Sequentially, revenue increased 9.5% over the first quarter of 2009. GAAP net income for the second quarter of 2009 was $12.9 million, or $0.08 per diluted share, compared to GAAP net income of $21.7 million, or $0.13 per diluted share, in the second quarter of 2008. Included in GAAP EPS in the second quarter of 2009 was non-cash stock-based compensation expense of ($0.01) per diluted share.
For the six months ended June 30, 2009, revenue was $483.0 million, a decrease of 12.2%, compared to revenue of $549.8 million in the first half of 2008. Excluding the effect of foreign currency translation, revenue for the six months ended June 30, 2009 decreased by 4.4% year-over-year. GAAP net income for the six months ended June 30, 2009 was $21.3 million, or $0.13 per diluted share, compared to GAAP net income of $20.9 million, or $0.13 per diluted share, during the six months ended June 30, 2008. Included in GAAP EPS for the six months ended June 30, 2009 was non-cash stock-based compensation expense of ($0.02) per diluted share.
Free cash flow for the second quarter of 2009 was $32.8 million. During the second quarter of 2009, Bruker repaid $34.1 million of debt, and ended the quarter with cash and cash equivalents of $154.3 million, and net debt of $16.4 million.
Comment and Outlook
Frank Laukien, Bruker’s President and CEO, commented: “Considering the challenging economic conditions in the industrial markets, we are pleased with our performance in the second quarter and first half of 2009. In the second quarter of 2009, we experienced solid top line growth sequentially, while the year-over-year revenue comparison was expected to be more difficult due to our revenue spike in the second quarter of 2008. On the bottom line, our cost-cutting measures, the strength of our new product lines and the impact of our business initiatives had a positive impact on our second quarter 2009 results, and contributed to our 54% sequential growth in net income.”
Dr. Laukien continued: “During the second quarter we continued to strengthen our product portfolio and launched several compelling mass spectrometry products at ASMS 2009, while also introducing the world’s first 1 Gigahertz NMR system. Our life-science mass spectrometry business delivered strong double-digit revenue growth and significant margin improvements in the second quarter of 2009. Moreover, after the acquisition of the ACCEL RI business by our Bruker Advanced Supercon business, we have established the new Bruker Energy & Supercon Technologies division, which is emerging as a global leader in superconductors and supercon devices, as well as in advanced technologies for energy research and next-generation grid infrastructure.”
Bruker’s Chief Financial Officer, Bill Knight, added: “While the downturn in the global economy continues to be challenging to navigate, we are relatively well positioned to handle these challenges with our strong technology and IP base, our high-performance product portfolio and our broad international diversification. Moreover, we derive nearly 70% of our revenue from universities and medical schools, as well as from other non-profit and government customers, who tend to be less sensitive to economic conditions. Going forward, we expect the global government stimulus programs to have a positive impact on our high-end life-science and research systems business, as well as on our new Bruker Energy & Supercon Technologies division, starting in the second half of 2009, accelerating in 2010, and continuing into 2011.”
Segment Information
After Bruker’s acquisition of the ACCEL Research Instruments business on April 1, 2009, starting with the second quarter of 2009, Bruker has established two new reportable segments:
1) The Bruker Scientific Instruments (BSI) segment consists of the four divisions Bruker AXS, Bruker BioSpin, Bruker Daltonics and Bruker Optics.
2) The new Bruker Energy & Supercon Technologies (BEST) segment which combines the acquired ACCEL RI business, and the superconductor and supercon devices business that was previously called Bruker Advanced Supercon, Inc.
Revenue in the BSI segment for the six months ended June 30, 2009 was $464.9 million, compared to BSI revenue of $533.5 million for the six months ended June 30, 2008. Excluding the effects of foreign currency translation, first half 2009 BSI revenue decreased by 5.4% year-over-year. BSI net income for the six months ended June 30, 2009 was $23.5 million, compared to $24.7 million for the six months ended June 30, 2008. BSI earnings per diluted share for the six months ended June 30, 2009 were $0.14, compared to $0.15 for the six months ended June 30, 2008.
Revenue in the BEST segment for the six months ended June 30, 2009 was $21.8 million, compared to BEST revenue of $22.4 million for the six months ended June 30, 2008. Excluding the effects of foreign currency translation, first half 2009 BEST revenue increased by 12.3% year-over-year. BEST net loss for the six months ended June 30, 2009 was ($3.4) million, compared to a net loss of ($4.0) million for the six months ended June 30, 2008. BEST loss per diluted share for the six months ended June 30, 2009 was ($0.02), compared to ($0.02) for the six months ended June 30, 2008.
Following at the end of this press release is a non-GAAP table reconciling the results of our reportable segments to the consolidated results of Bruker Corporation.
USE OF NON-GAAP FINANCIAL MEASURES
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the measures of non-GAAP revenue, non-GAAP operating income, non-GAAP net income and non-GAAP EPS, by reportable segment. We believe that such non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to previous periods or forecasts. However, the non-GAAP financial measures included in this press release are not meant to be a better presentation or a substitute for results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying table. Specifically:
* Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the six months ended June 30, 2009 and 2008
EARNINGS CONFERENCE CALL
Bruker Corporation will host an operator-assisted earnings conference call at 9:00 a.m. Eastern Daylight Time on Wednesday, July 29, 2009. To listen to the webcast, investors can go to http://ir.bruker.com and click on the live web broadcast symbol. The webcast will be available through the Company web site for 30 days. Investors can also listen and participate on the telephone in the US and Canada by calling 800-688-0796, or +1-617-614-4070 outside the US and Canada. Investors should refer to the Bruker Earnings Call. A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside the US and Canada, and then entering replay pass code 15184127. For more information, please visit http://ir.bruker.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Bruker Corporation
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in millions, except per share data)
Three Months Ended June 30, Six Months Ended June 30,
2009 2008 2009 2008
Product revenue $ 222.9 $ 280.3 $ 425.1 $ 488.6
Service revenue 28.3 30.2 55.2 58.9
Other revenue 1.3 1.0 2.7 2.3
Total revenue 252.5 311.5 483.0 549.8
Cost of product revenue 125.2 162.5 236.9 267.7
Cost of service revenue 16.1 19.4 32.2 38.5
Total cost of revenue 141.3 181.9 269.1 306.2
Gross profit 111.2 129.6 213.9 243.6
Operating Expenses:
Sales and marketing 43.9 47.1 86.5 91.5
General and administrative 17.0 17.2 33.3 34.0
Research and development 31.1 36.5 60.2 67.7
Acquisition related, net (1.0 ) 0.4 (0.6 ) 6.2
Total operating expenses 91.0 101.2 179.4 199.4
Operating income 20.2 28.4 34.5 44.2
Interest and other income (expense), net (2.9 ) 3.6 (2.8 ) (8.6 )
Income before income tax provision and
noncontrolling interest in consolidated subsidiaries 17.3 32.0 31.7 35.6
Income tax provision 4.6 10.3 10.4 14.5
Net income 12.7 21.7 21.3 21.1
Net income (loss) attributable to noncontrolling interests (0.2 ) - - 0.2
Net income attributable to Bruker Corporation $ 12.9 $ 21.7 $ 21.3 $ 20.9
Net income per common share attributable to:
Bruker Corporation shareholders:
Basic and diluted $ 0.08 $ 0.13 $ 0.13 $ 0.13
Weighted average shares outstanding:
Basic 163.3 162.4 163.3 162.4
Diluted 164.7 165.5 164.5 165.3
Bruker Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in millions)
June 30, December 31,
2009 2008
ASSETS
Current assets:
Cash, short-term investments and restricted cash $ 154.3 $ 167.7
Accounts receivable, net 132.9 171.9
Inventories 436.4 425.1
Other current assets 65.6 56.0
Total current assets 789.2 820.7
Property and equipment, net 221.3 221.3
Intangible and other assets 77.0 74.3
Total assets $ 1,087.5 $ 1,116.3
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings $ 43.1 $ 41.0
Accounts payable 40.8 43.3
Customer deposits 202.1 199.6
Other current liabilities 233.2 235.8
Total current liabilities 519.2 519.7
Long-term debt 127.6 182.8
Other long-term liabilities 104.2 101.1
Total shareholders' equity 336.5 312.7
Total liabilities and shareholders' equity $ 1,087.5 $ 1,116.3
Reconciliation of BSI and BEST reportable segments to the consolidated results of Bruker Corporation for the six months ended June 30, 2009 and 2008 (unaudited)
(in millions, except per share data)
Bruker
Bruker Energy & Corporate,
Scientific Supercon Adjustments
June 30, 2009: Instruments Technologies & Eliminations Consolidated
Revenue
$
464.9
$ 21.8 $ (3.7 ) $ 483.0
Operating Income 36.5 (3.1 ) 1.1 34.5
Net Income 23.5 (3.4 ) 1.2 21.3
Net Income Per Diluted Share $ 0.14 $ (0.02 ) $ 0.01 $ 0.13
Dulited Shares Outstanding 164.5 163.3 164.5 164.5
June 30, 2008:
Revenue $ 533.5 $ 22.4 $ (6.1 ) $ 549.8
Operating Income 47.7 (3.7 ) 0.2 44.2
Net Income 24.7 (4.0 ) 0.2 20.9
Net Income Per Diluted Share $ 0.15 $ (0.02 ) $ 0.00 $ 0.13
Dulited Shares Outstanding 165.3 162.4 165.3 165.3
MSC290
18年前
Bruker Biospin 950 mention
Campus Celebrates Historic Milestone
20 October 2008 - International Business Times
KANNAPOLIS, N.C., Oct. 20 /PRNewswire/ -- Academia, science, industry and government leaders gathered in Kannapolis, Monday, October 20th at 10 AM at the Dedication and Open House celebration for the David H. Murdock Core Laboratory Building, the UNC Nutrition Research Building and the NC State Fruit and Vegetable Science Institute Building. The UNC Nutrition Research Building is home to NC A&T University, NC Central University, UNC Chapel Hill and UNC Greensboro. NC State University, Appalachian State University, and Dole Food Company will occupy the NC State Fruit and Vegetable Science Institute Building at the NC Research Campus. UNC Charlotte will have tenure track faculty members located in the UNC Nutrition Building and the NC State Fruit and Vegetable Science Institute Building, and will also have a presence in the 311,000 square foot David H. Murdock Core Laboratory Building. "This campus fulfills my lifelong dream of being able to change the world's thoughts on nutrition and find ways to cure many of the dreadful diseases that have affected all of us and our families. It excites me to think of the groundbreaking research that will occur as a result of having these world class universities and companies here working together all in one place,"stated David Murdock.
Erskine B. Bowles, President of the UNC System along with Dr. Steven Leath, Vice President of Research for the UNC System and Dr. Victor J. Dzau,Chancellor for Health Affairs, Duke University and President and CEO, Duke University Health System spoke at the event. Dr. Stanley F. Battle,Chancellor, NC A&T University, Dr. Linda P. Brady, Chancellor, University of North Carolina Greensboro, Dr. Philip L. Dubois, Chancellor, University of North Carolina Charlotte, Dr. Charlie Nelms, Chancellor, North Carolina Central University, Dr. James L. Oblinger, Chancellor, North Carolina State University, Dr. Kenneth E. Peacock, Chancellor, Appalachian State University,and Vice Chancellor Dr. Tony G. Waldrop of the University of North Carolina Chapel Hill were on hand to represent each of their respective universities on the dais. In addition, representatives from a number of other universities within the UNC System were in attendance. President Erskine Bowles said, "I'm immensely proud that researchers and graduate students from seven UNC campuses are actively involved at the NC Research Campus, but what really energizes and excites me is all the cutting-edge research and life-altering discoveries that will happen within these world-class laboratories and facilities. With education, government, and the private sector working together in partnership,this Research Campus has enormous potential to create new jobs and spur economic development in our state."
Special guests included US Senator Elizabeth H. Dole, US Senator Richard M. Burr, US Congressman Robin C. Hayes, US Congressman J. Howard Coble, US Congressman Mel Watt, Lieutenant Governor Beverly E. Perdue, NC Secretary of State Elaine Marshall, along with former Governors James B. Hunt, Jr. and James G. Martin. Senator Marc Basnight, President Pro Tempore, NC Senate, and Speaker Joe Hackney, Speaker of the NC House of Representatives, along with NC Senator Fletcher L. Hartsell, Jr., led the delegation of area representatives from the NC Senate and NC House of Representatives to the dais. "This campus is a shining example of the future and vision of the state of North Carolina,"remarked Senator Fletcher Hartsell. "I am reminded of Thomas Jefferson's quote, 'I like the dreams of the future better than the history of the past.'I can only imagine what great discovery and promise lies ahead because of the collaboration on this campus." Senator Dole, Senator Burr, Congressman Hayes,Senator Basnight, and Senator Hartsell return to the campus after having been present for the announcement of the NC Research Campus on September 25, 2005and subsequent events in the development of the campus. The NC Research Campus is poised to generate 30,000 jobs for the state of North Carolina in the next12 - 15 years. "The North Carolina Research Campus will strengthen our state's standing as a national biotech leader, it will create new jobs, and its scientific innovations will improve the health and well-being of people around the world," said Lt. Governor Bev Perdue. "Biotechnology is the next frontier of health science and as new discoveries are made, North Carolina will lead the way." The Mayor of Kannapolis, Robert S. Misenheimer, along with many other dignitaries from surrounding counties and cities participated in the dedication ceremony and tours of the buildings. Dr. Carol Spalding, recently named as President of Rowan Cabarrus Community College, was seated on the dais representing the community college for the celebration.
In addition to academic institutions, top officials from a number of companies who will have a strong presence on the NC Research Campus were on hand for the event. Those companies include Carolinas Healthcare System, Cabarrus Health Alliance, Dole Food Company, LabCorp, Pharmaceutical Product Development, Sensory Spectrum, Anatomics, Red Hat, Lovelace Respiratory Research Institute and the Charlotte Research Institute. Researchers from academia, science and industry will be focused on studying health, nutrition,and agriculture. Primary areas of concentration are cancer, cardiovascular disease, diabetes, obesity, brain development, liver disease and osteoarthritis.
The ceremony was held at the main entrance on Research Campus Drive near the front steps into the David H. Murdock Core Laboratory Building. The public was invited to park in the new parking deck adjacent to the site of the event.
The 350 acre campus is a public-private venture created to foster collaboration and further knowledge in biotechnology, nutrition, agriculture,and health. The David H. Murdock Research Institute, located within the David H. Murdock Core Laboratory, will house the most state-of-the art scientific equipment in the areas of genomics, proteomics, metabolomics, animal and plant imaging, microscopy, and structural chemistry. In preparation for the opening of the campus, the DHMRI has purchased the first phase of equipment for the various core laboratories, including the Bruker Biospin 950 MHz NMR. In addition to the DHMRI initiative, David H. Murdock has invested $35 million ina longitudinal population-based research initiative led by Duke University to examine the behavioral and genetic differences in people that lead to the development of disease. The project, entitled the M.U.R.D.O.C.K Study, is an acronym for Measurement to Understand the Reclassification of Disease in Cabarrus/Kannapolis. It will be conducted on site by Duke University scientists and their collaborators and will span over a number of years."This beautiful, one-of-a-kind Core Laboratory is the heart of the Campus, and I believe it represents an unprecedented opportunity for scientists here to perform breakthrough research that can eventually transform the way we think about and practice medicine," said Dr. Victor Dzau.
Mr. Murdock's vision for the campus is for the NC Research Campus to be the epicenter of health, wellness and disease research in the world. The presence of vast scientific and human resources combined in a unique collaborative environment on the campus will increase the flow of information from the academic laboratory to industry, resulting in an improvement in the quality of life for people here and around the world. "The possible collaboration of the different entities at the NC Research Campus is endless and will be the start of a whole new era of collaborative research and innovation to benefit mankind," stated David Murdock. "And that's good news for a world needing to hear good news."
http://www.ibtimes.com/prnews/20081020/nc-research-campus.htm
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Monksdream
2年前
stocktrademan
11年前
Renee
12年前
Penny Roger$
14年前
メールアドレスで登録
